Combined therapy of photodynamic therapy and immune checkpoint inhibitor
Through the combination of porphyrin dimer salt photodynamic therapy and immune checkpoint inhibitors, the immune response is activated and subsequent immunotherapy is combined to solve the problems of recurrence and metastasis of esophageal cancer, and the effectiveness of treatment and the quality of life of patients are improved.
Patent Information
- Application Number
- PCT/CN2024/093175
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-28
AI Technical Summary
The recurrence rate of esophageal cancer is high, and the survival rate of patients with distant metastatic diseases is low. Existing treatment plans such as radiotherapy have high complications, local recurrence problems, and immunotherapy faces difficulties such as individual differences and insufficient immunogenicity, and lack of effective local Control therapy.
The combined therapy of porphyrin dimer salt-based photodynamic therapy and immune checkpoint inhibitors is used to activate the immune response through the photodynamic effect of photosensitizers in the tumor and used in combination with subsequent immunotherapy to improve the effectiveness of the treatment.
It significantly improves the local control effect of esophageal cancer, reduces the recurrence and metastasis rate, improves the quality of life and survival of patients, and provides systemic treatment for advanced esophageal cancer, enhances the basis of the immune system, and reduces drug resistance.
Smart Images

Figure PCTCN2024093175-FTAPPB-I100001 
Figure PCTCN2024093175-FTAPPB-I100002 
Figure PCTCN2024093175-FTAPPB-I100003
Abstract
Description
Combination therapy of photodynamic therapy and immune checkpoint inhibitors Field of the Invention
[0001] The present application relates to a combination therapy of photodynamic therapy and immune checkpoint inhibitors, in particular, to a combination therapy for treating systemic or local recurrent and / or metastatic cancer, in particular esophageal cancer. Background Art
[0002] Esophageal cancer (EC) is the ninth most common cancer worldwide and the sixth most common cancer in China. Curative treatment options for EC include surgery, radical chemoradiotherapy, and medical therapy. However, most patients have advanced disease at diagnosis. Even after radical surgery or chemoradiotherapy, EC recurrence rates remain high, and the five-year survival rate for patients with distant metastatic disease is only 4.8%.
[0003] The standard first-line treatment for EC is chemotherapy based on cisplatin + 5-Fu or paclitaxel. However, after progression on first-line treatment, systemic treatment options are limited and only effective in the short term. Radiotherapy is usually used for primary or locally recurrent tumors, but the high incidence of complications (such as radiation pneumonia, esophagitis, fistulas, and bleeding) worsens the patient's prognosis and affects the quality of life. Local recurrence after radiotherapy is a major problem faced by patients with esophageal cancer. In recent years, immunotherapy has gradually become a second-line treatment option for patients. Clinical studies have shown that second-line immunotherapy is effective for esophageal squamous cell carcinoma (ESCC), with a remission rate of 16.7%. However, the main difficulties faced by immunotherapy alone are multifaceted, including large individual differences, insufficient immunogenicity, and weak intervention in local primary or recurrent lesions. Therefore, there is an urgent need to develop new local control therapies with high remission rates for local esophageal cancer and distant metastatic lesions. Combining with other treatment options may be an effective way to improve the remission rate.
[0004] Photodynamic therapy (PDT) is a new method for treating diseases that utilizes the photodynamic effect of photosensitizers. It is currently used primarily for the treatment and diagnosis of malignant tumors, as well as certain precancerous and benign lesions. After being injected into the body, photosensitizers accumulate in relatively high concentrations within tumor tissue over a period of time. When irradiated with light of a specific wavelength, a strong photodynamic effect occurs, fully destroying the diseased tissue. PDT exhibits a certain degree of selectivity for target tissues and possesses good controllable killing properties. Therefore, it can minimize damage to normal tissue while ensuring tumor inactivation. It is a minimally invasive, low-toxic, non-thermogenic local treatment, and therefore has broad application prospects.
[0005] The present invention provides a combination therapy of photodynamic therapy based on a photosensitizer of a porphyrin dimer salt and an immune checkpoint inhibitor for treating locally recurrent cancer, particularly esophageal cancer.
[0006] Summary of the Invention
[0007] In one aspect, the present application provides a photosensitizer suitable for treating cancer in an individual, wherein the photosensitizer comprises a porphyrin dimer salt having a structure represented by formula (I), formula (II), or formula (III):
[0008] in
[0009] R is independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy and C 1-6 acyl, which is optionally substituted with one or more substituents selected from halogen and hydroxy,
[0010] M is an alkali metal, an alkaline earth metal or NH4 + ,
[0011] p is the reciprocal of the valence of M,
[0012] and solvates thereof, especially hydrates.
[0013] In certain embodiments, wherein R is independently selected from C optionally substituted with one or more hydroxyl groups 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Acyl, M is an alkali metal or NH4 + , and p is 1, and solvates thereof, especially hydrates.
[0014] In certain embodiments, wherein R is independently selected from -CH=CH2, -CH(OH)CH3, and -COCH3, M is an alkali metal or NH4 + , and p is 1, and solvates thereof, especially hydrates.
[0015] In certain embodiments, wherein R is independently selected from -CH=CH2 and -CH(OH)CH3, M is an alkali metal or NH4 + , and p is 1, and solvates thereof, especially hydrates.
[0016] In certain embodiments, wherein M is an alkali metal, such as Na or K.
[0017] In certain embodiments, the porphyrin dimer salt bound by an ether bond is selected from:
[0018] Bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether (DVDMS-1),
[0019] Bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether (DVDMS-2),
[0020] 1-[6,7-dipropionic acid sodium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionic acid sodium-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether (DVDMS-3),
[0021] Bis[1-[potassium 6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether,
[0022] Bis[1-[potassium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether,
[0023] 1-[6,7-dipropionate potassium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionate potassium-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether,
[0024] Bis[1-[6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether,
[0025] Bis[1-[6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether, and
[0026] 1-[6,7-dipropionatoammonium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionatoammonium-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether.
[0027] In certain embodiments, the porphyrin dimer salt is selected from the group consisting of DVDMS-1, DVDMS-2, DVDMS-3, and DVDMS-M (a mixture of DVDMS-1, DVDMS-2, and DVDMS-3).
[0028] In another aspect, the present application provides a method for treating cancer in an individual, comprising administering to the individual a therapeutically effective amount of a photosensitizer comprising a porphyrin dimer salt as disclosed herein, wherein the photosensitizer is administered in combination with an immune checkpoint inhibitor.
[0029] In certain embodiments, the cancer is esophageal cancer. In certain embodiments, the esophageal cancer can be classified by pathological type and selected from esophageal squamous cell carcinoma (ESCC), adenocarcinoma, mucoepidermoid carcinoma, small cell carcinoma, large cell carcinoma, neuroendocrine tumor, adenosquamous carcinoma, undifferentiated carcinoma, optionally, esophageal squamous cell carcinoma (ESCC) or adenocarcinoma. In certain embodiments, the esophageal cancer is advanced esophageal cancer, or optionally, locally advanced esophageal cancer. In certain embodiments, the esophageal cancer is recurrent esophageal cancer (optionally, locally recurrent esophageal cancer) and / or metastatic esophageal cancer (optionally, distant metastatic esophageal cancer).
[0030] In certain embodiments, the individual has received radiation therapy and / or chemotherapy.
[0031] In certain embodiments, the individual has previously received treatment for the primary lesion and / or metastatic lesion.
[0032] In certain embodiments, the esophageal cancer is resistant to at least one chemotherapy drug selected from the group consisting of a taxane anti-tumor chemotherapy drug, a fluoropyrimidine drug, and a platinum drug. In certain embodiments, the taxane anti-tumor chemotherapy drug is selected from the group consisting of paclitaxel and docetaxel. In certain embodiments, the fluoropyrimidine drug is selected from the group consisting of 5-fluorouracil, S-1, and capecitabine. In certain embodiments, the platinum drug is selected from the group consisting of cisplatin, carboplatin, and oxaliplatin.
[0033] In certain embodiments, the esophageal cancer exhibits resistance to immunotherapy.
[0034] In certain embodiments, the porphyrin dimer salt is administered in a range of 0.01-5 mg / kg body weight. In certain embodiments, the individual is subjected to photodynamic therapy using a laser 24-48 hours after administration of the porphyrin dimer salt. In certain embodiments, the wavelength of the laser is 631±3 nm, such as 630 nm, 631 nm, or 632 nm. In certain embodiments, the dose of the laser is 90-300 J / cm 2 .
[0035] In certain embodiments, the immune checkpoint inhibitor is administered to the individual some time after the laser application. In certain embodiments, the immune checkpoint inhibitor is administered to the individual 20 to 50 hours, preferably 24 to 48 hours, after the laser application.
[0036] In certain embodiments, the immune checkpoint inhibitor is selected from the group consisting of a PD-1 antagonist (PD-1 antibody), a PD-L1 antagonist (PD-L1 antibody). In certain embodiments, the PD-1 antibody is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, toripalimab, sintilimab, camrelizumab, tislelizumab, penpulimab, sepalimab, serplulimab, and putelimumab. In certain embodiments, the PD-L1 antibody is selected from Atezolizumab, Avelumab, Durvalumab, Envafolimab, and Sugemalimab.
[0037] In certain embodiments, the porphyrin dimer salt is sodium porphyrin (DVDMS), which is a sodium salt of a porphyrin dimer bound by an ether bond. In some embodiments, the sodium porphyrin has a structure represented by the above formula (I), formula (II), or formula (III). In certain embodiments, the porphyrin dimer salt is DVDMS-1, DVDMS-2, DVDMS-3, or DVDMS-M (i.e., a mixture of DVDMS-1, DVDMS-2, and DVDMS-3), and the immune checkpoint inhibitor is pembrolizumab.
[0038] On the other hand, the present application also provides the use of a photosensitizer as disclosed herein in the preparation of a drug for treating cancer in an individual, wherein the treatment includes the combination of the photosensitizer and an immune checkpoint inhibitor. In some embodiments, wherein the cancer is esophageal cancer. In some embodiments, the present application also provides the use of a photosensitizer as disclosed herein and an immune checkpoint inhibitor in the preparation of a drug for treating cancer in an individual. In some embodiments, the drug is used to implement the method for treating cancer disclosed in the present invention. In some embodiments, the photosensitizer and immune checkpoint inhibitor as disclosed herein are prepared in a form suitable for use in the method for treating cancer as disclosed in the present invention. On the other hand, the present application also provides a pharmaceutical composition. In some embodiments, the pharmaceutical composition comprises a photosensitizer as disclosed in the present invention. In some embodiments, the pharmaceutical composition is used to implement the method for treating cancer disclosed in the present invention.
[0039] In yet another aspect, the present application also provides a kit comprising a photosensitizer as disclosed herein. In some embodiments, the kit comprises a photosensitizer as disclosed in the present invention. In some embodiments, the kit is used to implement a method for treating cancer as disclosed in the present invention. In some embodiments, the kit further comprises an immune checkpoint inhibitor.
[0040] Without wishing to be bound by theory, in the combination therapy of photodynamic therapy and immunotherapy based on porphyrin dimer salt photosensitizer described in the present application, the photodynamic therapy has the characteristics of neoadjuvant therapy such as intervention and combination in immunotherapy. The immunogenicity in the patient's body is first activated preferentially by photodynamic therapy, which provides a higher immune system foundation for subsequent immunotherapy means or drugs, strengthens the activity of immunotherapy cells, and improves the therapeutic effectiveness of the combination therapy. The combination therapy described in the present application is suitable for treating various types of cancer, especially esophageal cancer, and especially provides a new systemic treatment method for advanced esophageal cancer with poor frontline treatment effect. It has a comprehensive inhibitory effect on primary and even systemic spread tumors, which is conducive to effectively clearing cancer cells and reducing the chance of cancer cell recurrence and / or metastasis. The combination therapy described in the present application can also be further combined with other treatment means. For example, after surgical treatment of the lesion, the combination therapy described in the present application is used for secondary intervention and clearance treatment to enhance the clearance rate of cancer cells, reduce the recurrence rate of tumors, and improve the survival rate of patients. DETAILED DESCRIPTION
[0041] The following description of the present application is only intended to illustrate the various embodiments of the present application. Therefore, the specific modifications discussed should not be interpreted as limiting the scope of the present application. It will be apparent to those skilled in the art that various equivalents, variations and modifications can be made without departing from the scope of the present application, and it should be understood that these equivalent embodiments will be included herein. All references cited in this application, including publications, patents and patent applications, are incorporated herein by reference in their entirety.
[0042] The present application provides a combination therapy of photodynamic therapy and immunotherapy based on a porphyrin dimer salt photosensitizer for treating cancer in an individual, comprising administering to the individual a therapeutically effective amount of a photosensitizer comprising a porphyrin dimer salt, the photosensitizer being administered in combination with an immune checkpoint inhibitor. The combination therapy is suitable for treating various types of cancer, such as systemic or local recurrent and / or metastatic cancer, particularly esophageal cancer.
[0043] Esophageal cancer
[0044] As used herein, the terms "cancer," "malignancy," "tumor," and "cancer" are used interchangeably herein to refer to cells that exhibit relatively abnormal, uncontrolled, and / or autonomous growth, such that the cells exhibit an abnormal growth phenotype characterized by significantly uncontrolled cell proliferation. As used herein, the terms "cancer," "malignancy," "tumor," and "cancer" may include primary or metastatic.
[0045] The term "esophageal cancer" refers to tumors that develop in the esophageal epithelium. Pathologically classified, esophageal cancer includes, but is not limited to, esophageal squamous cell carcinoma (ESCC), adenocarcinoma, mucoepidermoid carcinoma, small cell carcinoma, large cell carcinoma, neuroendocrine tumor, adenosquamous carcinoma, or undifferentiated carcinoma. In some embodiments, the esophageal cancer is esophageal squamous cell carcinoma (ESCC) or adenocarcinoma.
[0046] In some embodiments, the esophageal cancer described herein includes advanced esophageal cancer. In some embodiments, the esophageal cancer is locally advanced esophageal cancer.
[0047] The stage of esophageal cancer is determined according to the TNM staging standard based on the extent of cancer invasion. Generally speaking, in oncology, esophageal cancer in TNM stage I and II is determined to be early esophageal cancer, and TNM stage III and IV are determined to be advanced esophageal cancer or locally advanced esophageal cancer. The term "locally advanced esophageal cancer" generally refers to esophageal cancer that has cancerized and invaded the esophagus and surrounding tissues, but has no invasion of important organs and no distant metastasis. In some embodiments, the locally advanced esophageal cancer includes esophageal cancer that has failed first-line treatment, second-line treatment, or even third-line treatment, for example, with the following characteristics: lymph node and distant metastasis already exist, the patient's basic physical condition is poor, and treatment methods aimed at radical treatment are no longer achievable.
[0048] The term "first-line therapy" refers to the initial round of treatment after diagnosis, which is the most effective and least side-effective regimen. It is also called primary therapy or therapy, and its goal is to effectively inhibit tumor progression, if possible. The term "second-line therapy" refers to treatment after first-line therapy, when the patient's tumor progresses again and becomes resistant to the first-line regimen, requiring a different regimen with a different anti-cancer mechanism. The term "third-line therapy" refers to treatment after failure of second-line therapy, when a different regimen is used, typically with fewer available drugs and effective treatment options.
[0049] In some embodiments, the esophageal cancer is recurrent esophageal cancer. In some embodiments, the esophageal cancer is locally recurrent esophageal cancer. The term "recurrent esophageal cancer" refers to the reappearance of a tumor of the same type as the original esophageal cancer after the original esophageal cancer has resolved after treatment. In some embodiments, the recurrent esophageal cancer is systemic recurrent esophageal cancer or locally recurrent esophageal cancer.
[0050] In some embodiments, the esophageal cancer is metastatic esophageal cancer. In some embodiments, the esophageal cancer is distant metastatic esophageal cancer. The term "metastatic esophageal cancer" refers to a situation in which, in addition to the primary esophageal lesion, the cancer metastasizes to adjacent sites or distant organs through the lymph or blood, respectively. The term "distant metastatic esophageal cancer" refers to a metastasis that spreads to a distant site from the primary esophageal cancer lesion. For example, if esophageal cancer that was originally in the lower esophagus metastasizes to the lymph nodes above the clavicle, it can be considered as distant metastatic esophageal cancer that has metastasized to distal lymph nodes. For another example, if esophageal cancer that was originally in the neck metastasizes to the lymph nodes in the neck, it can be considered as a metastasis to the proximal lymph nodes.
[0051] In some embodiments, the recurrent or metastatic esophageal cancer has caused esophageal obstruction, preventing the patient from eating or drinking independently. One of the current primary treatments for this type of esophageal cancer is to open the esophagus, improve the patient's difficulty eating, and increase their nutritional needs, thereby enhancing the effectiveness of palliative care. Currently, in addition to palliative chemoradiotherapy, the primary treatment options for opening the esophagus include physical therapies such as esophageal stent ablation, electrosurgical resection, and balloon dilatation. However, these methods all have significant drawbacks. They only provide a temporary physical dilation effect and cannot address recurrence and obstruction of esophageal cancer in the esophagus, nor can they truly eliminate cancer cells in the esophagus. The combined photodynamic therapy and immunotherapy based on porphyrin dimer salt photosensitizers described in this application unexpectedly effectively addresses the above-mentioned issues. On the one hand, by leveraging the large accumulation of photosensitizers in the tumor, photodynamic therapy can kill tumor cells under specific wavelengths of light. On the other hand, after photodynamic therapy destroys tumor cells, it can release a large amount of tumor antigens, which will preferentially activate the patient's immune response and enhance the immune system foundation. The inventors of this application have discovered that when combined with subsequent immunotherapy methods or drugs, the activity of immune cells can be significantly enhanced, and the effectiveness of patient treatment can be improved, thereby solving the problem of esophageal obstruction caused by esophageal cancer, fundamentally suppressing the chance of tumor recurrence, solving the problem of self-feeding for patients, greatly improving the patient's life treatment and nutritional support, and also laying a good treatment foundation for subsequent palliative treatment, which is beneficial to the continuation of the patient's survival.
[0052] In some embodiments, the esophageal cancer described herein also includes esophageal cancer that exhibits resistance to at least one of immunotherapy and chemotherapy. In the present application, "drug resistance" refers to the fact that after a certain period of treatment, a resistance mechanism has developed in the patient's body to a therapeutic agent (e.g., immunotherapy and / or chemotherapy), resulting in resistance or non-response, and the patient is unable to benefit from the therapeutic effect of the drug again. For example, even if the patient receives treatment with a therapeutic agent, the number of tumor cells still increases. The drug resistance may be that which occurs before treatment (i.e., primary), or that which is produced after treatment (i.e., acquired, or recurrent). Without wishing to be bound by theory, the porphyrin dimer salt described herein belongs to a porphyrin photosensitizer, and porphyrin is an essential substance in the synthesis of human erythrocytes. A large amount of porphyrin substances exist in the human body, so after the porphyrin photosensitizer is run in the body, the immune system is insensitive to porphyrin drugs and lacks a resistance mechanism, so that the photosensitizer described herein can be used for single, multiple, or even high-frequency treatment without losing the effectiveness of tumor treatment. Therefore, the combination therapy described in the present application is not likely to produce drug resistance in the patient's body and can still function stably after a certain period of use.
[0053] In some embodiments, the esophageal cancer described herein exhibits resistance to one or more chemotherapeutic drugs.
[0054] As used herein, "chemotherapy" refers to biological (macromolecule) or chemical (small molecule) compounds that can be used to treat cancer. The types of chemotherapy drugs include, but are not limited to, histone deacetylase inhibitors (HDACIs), alkylating agents, antimetabolites, alkaloids, cytotoxic / anticancer antibiotics, topoisomerase inhibitors, tubulin inhibitors, proteins, antibodies, kinase inhibitors, etc. Chemotherapy drugs include compounds used for targeted therapy and compounds used in non-targeted conventional chemotherapy.
[0055] In some embodiments, the esophageal cancer exhibits resistance to at least one chemotherapy, which may be any conventional chemotherapy known in the art or standard chemotherapy in the clinic, including but not limited to the following drugs or combinations thereof: taxane anti-tumor chemotherapy drugs, fluorouracil drugs, platinum drugs, antifolate drugs, topoisomerase inhibitors. Examples of taxane anti-tumor chemotherapy drugs include, for example, paclitaxel compounds and docetaxel compounds. Examples of fluorouracil drugs include, for example, 5-fluorouracil, Tegafur (i.e., a combination of tegafur, gimeracil and oteracil), capecitabine, etc. Examples of platinum drugs include, for example, cisplatin, carboplatin, oxaliplatin, nedaplatin, etc. Examples of antifolate drugs include methotrexate, pemetrexed, etc. Examples of topoisomerase inhibitors include irinotecan.
[0056] In some embodiments, the esophageal cancer includes but is not limited to showing resistance to at least one chemotherapy drug regimen selected from the following groups: commonly used chemotherapy regimens for advanced ESCC, including cisplatin combined with fluorouracil or paclitaxel combined with platinum drugs, etc.; commonly used chemotherapy regimens for advanced esophageal gastric junction adenocarcinoma, including cisplatin or oxaliplatin combined with fluorouracil drugs, etc.; first-line treatment regimens for esophageal cancer patients with good physical condition, including a three-drug combination regimen of taxanes combined with platinum and fluorouracil drugs.
[0057] In some embodiments, the esophageal cancer described herein exhibits resistance to one or more immunotherapies.
[0058] "Immunotherapy," as used herein, refers to a treatment approach that utilizes a patient's own immune cells to eliminate cancer by enhancing and activating their function. Examples of immunotherapy include, but are not limited to, molecularly targeted therapy; immune checkpoint inhibitors (e.g., PD-1 / L1 inhibitors and CTLA-4 inhibitors); adoptive immune cell therapy (e.g., CAR-T, TIL, NK, CIK / DC-CIK); cytokine therapy; or tumor vaccines.
[0059] In some embodiments, the esophageal cancer described herein exhibits resistance to an immune checkpoint inhibitor.
[0060] The term "immune checkpoint inhibitor" in this article refers to drugs that can target immune checkpoint molecules, relieve the inhibition of tumor cells on immune cells, and prompt immune cells to reactivate and recognize / kill cancer cells.
[0061] In some embodiments, the immune checkpoint inhibitor is a PD-1 antagonist (PD-1 antibody) or a PD-L1 antagonist (PD-L1 antibody).
[0062] In some embodiments, the PD-1 antibody includes but is not limited to: Pembrolizumab, Nivolumab, Cemiplimab, Toripalimab, Sintilimab, Camrelizumab, Tislelizumab, Penpulimab, Sepalimab, Serplulimab and Putelimumab.
[0063] In some embodiments, the PD-L1 antibodies include but are not limited to Atezolizumab, Avelumab, Durvalumab, Envafolimab, and Sugemalimab.
[0064] In some embodiments, the esophageal cancer described herein exhibits resistance to at least one immunotherapy.
[0065] In some embodiments, the esophageal cancer described herein exhibits resistance to at least one of the PD-L1 antibody or PD-1 antibody.
[0066] In some embodiments, the resistance to immunotherapy can be any conventional immunotherapy regimen known in the art or a clinical standard immunotherapy regimen, including but not limited to the following drug regimens: a second-line treatment regimen for patients with advanced esophageal squamous cell carcinoma (ESCC) who have failed first-line chemotherapy, such as carrelizumab or tislelizumab; a second-line treatment regimen for ESCC patients with PD-L1 CPS>10 who have failed first-line chemotherapy, such as pembrolizumab monotherapy; a third-line and subsequent treatment regimen for patients with esophagogastric junction adenocarcinoma who have failed at least two lines of chemotherapy, such as nivolumab; a third-line and subsequent treatment regimen for HER-2-positive advanced esophageal gastric junction cancer, such as vedicizumab, an antibody-drug conjugate targeting HER-2. Vedotin); third-line and subsequent treatment drug regimens for patients with advanced esophagogastric junction cancer, such as the anti-angiogenic targeted drug apatinib; second-line and subsequent treatment drug regimens for patients with advanced ESCC, such as anlotinib or apatinib.
[0067] In some embodiments, the esophageal cancer described herein is esophageal cancer that exhibits resistance to combined immunotherapy and chemotherapy.
[0068] In some embodiments, the esophageal cancer includes but is not limited to showing resistance to the following combined therapeutic drug regimen: a first-line treatment regimen for patients with HER-2-positive advanced esophagogastric junction adenocarcinoma, comprising combining trastuzumab with cisplatin and fluorouracil.
[0069] In some embodiments, the individual suffering from the esophageal cancer (eg, an individual exhibiting drug resistance) has previously received radiation therapy and / or chemotherapy.
[0070] In some embodiments, the individual suffering from the esophageal cancer (eg, an individual exhibiting drug resistance) has previously received treatment for the primary or metastatic lesion.
[0071] photosensitizers
[0072] The photosensitizer herein includes a porphyrin dimer salt. In the present application, a porphyrin dimer salt refers to a compound structure having two porphyrin structures connected by covalent bonding or a linker.
[0073] In some embodiments, the porphyrin dimer salt has a structure represented by the following formula (I), formula (II), or formula (III):
[0074] in
[0075] R is independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy and C 1-6 acyl groups,
[0076] which is optionally substituted with one or more substituents selected from halogen and hydroxy,
[0077] M is an alkali metal, an alkaline earth metal or NH4 + ,
[0078] p is the reciprocal of the valence of M,
[0079] and solvates thereof, especially hydrates.
[0080] In this application, “C 1-6 "Alkyl" means a branched or linear monovalent saturated hydrocarbon group having 1 to 6 carbon atoms. Preferably C 1-4 Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.
[0081] In this application, “C 2-6 "Alkenyl" means a linear or branched monovalent unsaturated hydrocarbon group having 2 to 6 carbon atoms and containing one or more double bonds. 2-4 Examples include, but are not limited to, vinyl, prop-1-enyl, allyl, but-1-enyl, pent-1-enyl, pent-1,4-dienyl, and the like.
[0082] In this application, “C 2-6 "Alkynyl" means a linear or branched monovalent unsaturated hydrocarbon group having 2 to 6 carbon atoms and containing one or more triple bonds. 2-4Examples include, but are not limited to, ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, pent-1-ynyl, pent-1,3-diynyl, and the like.
[0083] In this application, “C 1-6 "Alkoxy" means a group R'-O-, wherein R' is a C 1-6 Alkyl. Preferably C 1-4 Alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, and n-hexoxy.
[0084] In this application, “C 1-6 "Acyl" means a group R'-C(O)-, wherein R' is H or a monovalent saturated hydrocarbon radical having 1 to 5 carbon atoms, which is branched or straight chain. Preferably C 1-4 Examples include, but are not limited to, formyl, acetyl, propionyl, butyryl, valeryl, and hexanoyl.
[0085] In this application, "optional" or "optionally" means that the subsequently described event or circumstance can occur but does not have to occur, and the description includes instances where the event or circumstance occurs and instances where it does not. For example, "C 1-6 "C alkyl . . . , which is optionally substituted by one or more substituents selected from halogen and hydroxy" means a C alkyl group which may be, but is not necessarily, substituted by one or more halogen and / or hydroxy. 1-6 Alkyl, this description includes unsubstituted C 1-6 Alkyl and C substituted by one or more halogen and / or hydroxyl groups 1-6 alkyl.
[0086] In the present application, "halogen" means fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine, more preferably fluorine and chlorine.
[0087] In this application, "hydroxy" refers to the group -OH.
[0088] In this application, "valence" means the number of shared electron pairs formed by one atom of a chemical element. The valence of an ion is equal to its charge. For example, alkali metals and NH4 + The valence of is 1, and the valence of alkaline earth metals is 2.
[0089] As used herein, "solvate" refers to a solvent addition form formed by the attraction of solvent molecules to the ether-bonded porphyrin dimer salt described herein. If the solvent is water, the solvate formed is a hydrate, such as a monohydrate or dihydrate; if the solvent is an alcohol, the solvate formed is an alcoholate, such as an addition form with methanol or ethanol.
[0090] In some embodiments, R is independently selected from C optionally substituted with one or more hydroxyl groups. 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Acyl, M is an alkali metal or NH4 + , and p is 1.
[0091] In some embodiments, R is independently selected from -CH=CH2, -CH(OH)CH3 and -COCH3, M is an alkali metal or NH4 + , and p is 1.
[0092] In some embodiments, R is independently selected from -CH=CH2 and -CH(OH)CH3, M is an alkali metal or NH4 + , and p is 1.
[0093] In some embodiments, M is an alkali metal.
[0094] In some embodiments, M is Na or K.
[0095] In some embodiments, the porphyrin dimer salt bound by an ether bond is selected from the group consisting of: bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether, bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether, 1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl1-[6',7'-sodium dipropionate-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethylether, bis[1-[potassium 6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether, bis[1-[potassium 6,7-dipropionate-1,3,5,8-tetramethyl-2- Vinyl-4-porphine]ethyl]ether, 1-[6,7-dipropionate potassium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionate potassium-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether, bis[1-[6,7-dipropionate ammonium-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl] porphine]ethyl] ether, di[1-[6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether, and 1-[6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionate-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether.
[0096] In some embodiments, the porphyrin dimer salt is sodium dithiocarbamate (DVDMS), which is a sodium salt of a porphyrin dimer bound by an ether bond. In some embodiments, the sodium dithiocarbamate has the structure shown in the above formula (I), formula (II) or formula (III).
[0097] In some embodiments, the porphyrin dimer salt is bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether (DVDMS-1), bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether (DVDMS-2), 1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-sodium dipropionate-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethylether (DVDMS-3), or a mixture of the three (DVDMS-M).
[0098] More information about the photosensitizer comprising a porphyrin dimer salt is described in CN102030765B, the disclosure of which is incorporated herein in its entirety. In some embodiments, the photosensitizer of the present invention is used to implement the treatment methods disclosed herein.
[0099] Combination therapy
[0100] The present application provides a combination therapy of photodynamic therapy and immunotherapy based on a porphyrin dimer salt photosensitizer for treating cancer in an individual, which comprises administering a therapeutically effective amount of a porphyrin dimer salt photosensitizer to the individual, wherein the photosensitizer is used in combination with an immune checkpoint inhibitor.
[0101] In this application, the term "combination therapy" means that when two or more drugs are used in combination, they can be administered simultaneously, in overlapping time periods, or sequentially. The routes of administration of the two drugs in combination can be the same or different.
[0102] In this application, the term "treat" means to alleviate one or more symptoms associated with a disease, delay or prevent the progression or worsening of a disease, or cure a disease. For cancer (e.g., esophageal cancer), treatment can include curbing cancer development, reducing its severity, slowing its growth, inhibiting its metastasis, and reducing recurrence. However, treatment does not require that the disease or its associated symptoms be completely eliminated.
[0103] In this application, the term "subject" refers to animals, including mammals and non-mammals. Mammals refer to any member of the mammalian class, including but not limited to humans, non-human primates (such as chimpanzees and other apes and monkeys), farm animals (such as cattle, horses, sheep, goats and pigs), domestic animals (such as rabbits, dogs and cats), laboratory animals (including rodents such as rats, mice and guinea pigs), etc. Examples of non-mammals include but are not limited to birds, etc.
[0104] As used herein, the term "therapeutically effective amount" means that amount of a compound of the invention or combination therapy that produces the biological or medical response that is being sought or desired by the researcher or clinician.
[0105] In the present application, the photosensitizer disclosed herein can be formulated into any suitable form and can be applied by any suitable route, can be formulated into solutions, suspensions, emulsions, lyophilized preparations, etc. for injection (e.g., intra-arterial, intravenous, intramuscular, subcutaneous, intraperitoneal injection, etc.) or infusion administration, formulated into tablets, solutions, capsules, etc. for oral administration, formulated into ointments, creams, suppositories, patches, etc. for topical administration, formulated into aerosols, sprays, powders, etc. for inhalation administration. Preferred modes of administration are generally injection infusion, oral and topical administration. Injection / infusion administration can allow the compound of the present invention to quickly reach distribution equilibrium, for example, within 24 hours.
[0106] In certain embodiments, the porphyrin dimer salt is administered in a range of 0.01-5 mg / kg body weight, for example, 0.05-4 mg / kg body weight, 0.1-2 mg / kg body weight, or 0.2 mg-1 mg / kg body weight.
[0107] In certain embodiments, the porphyrin dimer salt is administered to the individual using a laser for a period of time after administration. Preferably, the porphyrin dimer salt is administered to the individual using a laser for photodynamic therapy 24-48 hours, especially 24 hours after administration. In certain embodiments, the wavelength of the laser is 631±3 nm, such as 630 nm, 631 nm or 632 nm. In certain embodiments, the dose of the laser is 60-300 J / cm 2 , 70-300J / cm 2 , 80-300J / cm 2 , 90-300J / cm 2 、90-290J / cm 2 、90-280J / cm 2 、90-270J / cm 2 , 90-260J / cm 2 , 90-250J / cm 2, 90-240J / cm 2 、90-230J / cm 2 、90-220J / cm 2 、90-210J / cm 2 , 90-200J / cm 2 , 90-190J / cm 2 , 90-180J / cm 2 , 90-170J / cm 2 , 90-160J / cm 2 , 90-150J / cm 2 , 90-140J / cm 2 , 90-130J / cm 2 , 90-120J / cm 2 , 100-120J / cm 2 , 100-110J / cm 2 , preferably, 90-300 J / cm 2 In certain embodiments, for advanced esophageal cancer that has caused near-complete obstruction, the laser dose is 200 J / cm 2 .
[0108] In this application, "immune checkpoint inhibitors" refer to drugs that can target immune checkpoint molecules, relieve the inhibition of tumor cells on immune cells, and promote the reactivation of immune cells to recognize / kill cancer cells.
[0109] In some embodiments, the immune checkpoint inhibitor is a PD-1 antagonist (PD-1 antibody) or a PD-L1 antagonist (PD-L1 antibody).
[0110] In some embodiments, the PD-1 antibody includes but is not limited to: Pembrolizumab, Nivolumab, Cemiplimab, Toripalimab, Sintilimab, Camrelizumab, Tislelizumab, Penpulimab, Sepalimab, Serplulimab and Putelimumab.
[0111] In some embodiments, the PD-L1 antibodies include but are not limited to Atezolizumab, Avelumab, Durvalumab, Envafolimab, and Sugemalimab.
[0112] In certain embodiments, the immune checkpoint inhibitor is administered to the individual after a period of time after the photodynamic therapy is applied. In certain embodiments, the immune checkpoint inhibitor is administered to the individual 20 to 50 hours, particularly 24 to 48 hours, after the laser application. In certain embodiments, compared with the DVDMS-PDT alone treatment regimen, the combination therapy of DVDMS-PDT and PD-1 antibody can significantly reduce the tumor growth rate in the mouse model and has a significantly enhanced anti-tumor effect. In certain embodiments, PD-1 antibody treatment between 24 and 48 hours after DVDMS-PDT has a more excellent anti-tumor effect, with a tumor inhibition rate of more than 98%.
[0113] In certain embodiments, the porphyrin dimer salt is DVDMS-1, DVDMS-2, DVDMS-3, or DVDMS-M, and the immune checkpoint inhibitor is a PD-1 antibody, such as pembrolizumab.
[0114] Example
[0115] Material:
[0116] 1. Test drugs and instruments
[0117] 1.1 Test drugs
[0118] DVDMS-2 sodium porphyrin for injection (Shanghai Guangsheng Pharmaceutical Co., Ltd.);
[0119] Pembrolizumab (purchased from Merck).
[0120] 1.2 Lighting equipment
[0121] 630nm semiconductor laser therapy device (XINGDA PDT 630II), laser wavelength meter (THORLABS), laser power meter (PM310D), equipped with Microlens optical fiber.
[0122] 2. Tumor cell lines
[0123] Human esophageal cancer Eca-109 cell line was purchased from China Center for Type Culture Collection (CCTCC) in Wuhan.
[0124] 3. Experimental Animals
[0125] Female nu / nu nude mice, weighing 18-22 g, were provided by Shanghai Slake Laboratory Animal Co., Ltd.
[0126] Example 1. Efficacy of combined therapy of daptomycin sodium-mediated photodynamic therapy (DVDMS-PDT) and PD-1 antibody in the human esophageal cancer Eca-109 mouse model
[0127] Objective: To observe the inhibitory effect of DVDMS-PDT combined with PD-1 antibody (pembrolizumab) on the growth of human esophageal cancer Eca-109 xenograft tumors in nude mice, optimize the time window between DVDMS-PDT and PD-1 antibody treatment, and provide a reference for clinical application.
[0128] plan:
[0129] 1. Preparation of Human Esophageal Cancer Model
[0130] Human esophageal cancer Eca-109 cells in the logarithmic growth phase were collected and diluted to 5*10 7 At a cell concentration of 100 cells / mL, 0.1 mL of the cell culture medium was injected subcutaneously at the right thigh of each nude mouse. After 7-10 days, a tumor was observed growing to a diameter of approximately 5-8 mm in the subcutaneous region of the right thigh of the nude mouse.
[0131] 2. Study the effect of PD-1 antibody treatment at different time windows after DVDMS-PDT on tumor growth
[0132] Select the qualified tumor-bearing mouse model as described above, measure the length and width of the tumor with a vernier caliper, and stratify and group the mice according to the size of the tumor, with 6 mice in each group. The injection of sodium porphyrin DVDMS-2 solution was prepared 24 hours before the experiment and refrigerated in the dark before use. DVDMS-2 was administered via the tail vein at a dose of 2 mg / kg body weight (Day-1), and PDT treatment was performed 24 hours later (Day 0). When implementing tumor illumination, first adjust the 630nm semiconductor laser used so that the output power of the optical fiber end is locked at 250mW, and then point the optical fiber with a microlens at the end directly at the target site, so that the laser is projected vertically and completely covers the tumor, and the spot diameter is maintained at 10mm. The therapeutic laser dose is approximately 70J / cm 2 .
[0133] PD-1 antibody (pembrolizumab) was administered some time after the end of DVDMS-PDT. According to the experimental groups, PD-1 antibody treatment was performed on each group at the time intervals shown in Table 1.
[0134] After combined treatment, the animals were observed for tumor growth and toxicity. Except for illumination of the tumor, mice were kept in a dark environment for three days after tail vein administration, followed by low-light conditions. On Day 21 after DVDMS-PDT, the animals were sacrificed, and tumors were excised and weighed. The tumor inhibition effect of each group was evaluated, and the tumor growth inhibition rate was calculated using the relative tumor proliferation rate (T / C) (%), calculated using the following formula:
[0135] T / C (%) = [RTV of treatment group (T) / RTV of negative control group (C)] × 100%.
[0136] Table 1
[0137] Conclusion: As shown in Table 1, compared with DVDMS-PDT alone, the combination of DVDMS-PDT and PD-1 antibody therapy significantly reduced tumor growth in the mouse model and demonstrated a significantly enhanced anti-tumor effect. Furthermore, 24-48 hours after DVDMS-PDT is a more optimal window for immunotherapy. The results showed that treatment with DVDMS-PDT less than 24 hours or more than 48 hours post-treatment was more effective than the control group. Furthermore, treatment with PD-1 antibodies between 24 and 48 hours post-DVDMS-PDT was even more effective, achieving a tumor inhibition rate exceeding 98%. No significant toxicity was observed in any of the treated groups.
[0138] Example 2. Therapeutic effect of combined DVDMS-PDT and PD-1 antibody therapy in clinical cases of advanced esophageal cancer
[0139] An 80-year-old patient with advanced esophageal cancer presented with swallowing abnormalities. The pathological diagnosis was esophageal squamous cell carcinoma (ESC), high-grade intraepithelial neoplasia with focal invasion, lymph node and distal metastasis, and pathological stage T4N3M1. After six cycles of systemic chemotherapy (paclitaxel + cisplatin), the patient's disease progressed significantly, with near-complete esophageal obstruction and inability to eat. Esophageal cancer treatment guidelines no longer recommended treatment options, with an expected survival of three to six months.
[0140] In order to improve the patient's esophageal obstruction, thereby improving the patient's eating condition and improving the patient's quality of life, the researchers used the combination therapy of DVDMS-PDT and PD-1 antibody (pembrolizumab) described in this application on the patient.
[0141] plan:
[0142] The patients were administered DVDMS-2 at a dose of 0.2 mg / kg body weight, and PDT treatment was performed 24 hours later. The wavelength of the treatment light was 630 ± 3 nm, and the treatment light dose was 200 J / cm 2 The patient was given pembrolizumab 200 mg per dose 24 hours after PDT and continued to receive pembrolizumab every three weeks.
[0143] After one week of combined DVDMS-PDT and PD-1 antibody treatment, the patient's esophageal obstruction had significantly improved, and he was able to consume a semi-liquid diet. He continued to receive pembrolizumab for a total of six cycles, and his disease remained stable. He subsequently discontinued treatment for personal reasons and remains alive at the fourth year of long-term follow-up.
[0144] Conclusion: The combination of DVDMS-PDT and PD-1 antibody has the effect of systemically controlling disease progression, inhibiting tumor recurrence and metastasis, and improving patients' eating conditions for patients with advanced esophageal cancer, especially those in the terminal stage. It is beneficial to the extension of patients' survival and improves their quality of life.
[0145] Example 3. Clinical trial of DVDMS-PDT combined with immunotherapy drugs
[0146] Participants: Patients aged ≥18 years with histologically confirmed esophageal squamous cell carcinoma (ESCC), radiographically confirmed metastatic ESCC, and who have failed at least one first-line metastatic systemic therapy.
[0147] Regimen: Patients meeting the above criteria received intravenous injection of varporphyrin sodium DVDMS-2 (Day-1), received PDT to treat the primary ESCC lesion 24 hours after DVDMS-2 administration (Day 0), and received immunotherapy with a fixed-dose intravenous infusion of 200 mg of PD-1 antibody (e.g., pembrolizumab or other selected PD-1 antibody or PD-L1 antibody) 24 hours after DVDMS-PDT (Day 1). Subsequently, they received immunotherapy every 21 days (one immunotherapy cycle per 21 days) for 8 cycles.
[0148] On day 30 after DVDMS-PDT, esophagogastroscopy (OGD) was performed to evaluate the efficacy of treatment of the primary lesions and to determine whether DVDMS-PDT was necessary again.
[0149] Expected results:
[0150] 1. Neoantigens will be produced at the primary site of ESCC undergoing DVDMS-PDT, enhancing the efficacy of immunotherapy and the inhibition of tumor growth, metastasis, and recurrence;
[0151] 2. The combination of DVDMS-PDT and immunotherapy drugs can enhance the efficacy of immunotherapy on primary lesions and metastatic lesions, and improve the objective response rate (ORR) and duration of response (DOR);
[0152] 3. Combination therapy of DVDMS-PDT and immunotherapy drugs can improve the quality of life (QoL) of ESCC patients;
[0153] 4. The combination of DVDMS-PDT and immunotherapy drugs can prolong the progression-free survival (PFS) of ESCC patients;
[0154] 5. The combination of DVDMS-PDT and immunotherapy drugs can prolong the overall survival (OS) of ESCC patients.
[0155] While the present application has been particularly shown and described with reference to specific embodiments, some of which are preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the application disclosed herein.
Claims
1. A method for treating cancer in an individual, comprising administering to the individual a therapeutically effective amount of a photosensitizer comprising a porphyrin dimer salt, the photosensitizer being administered in combination with an immune checkpoint inhibitor, optionally wherein the cancer is esophageal cancer.
2. The method of claim 1, wherein the esophageal cancer is selected from the group consisting of esophageal squamous cell carcinoma (ESCC), adenocarcinoma, mucoepidermoid carcinoma, small cell carcinoma, large cell carcinoma, neuroendocrine tumor, adenosquamous carcinoma, and undifferentiated carcinoma, optionally, the esophageal cancer is esophageal squamous cell carcinoma (ESCC) or adenocarcinoma.
3. The method of claim 1, wherein the esophageal cancer is advanced esophageal cancer, or alternatively, locally advanced esophageal cancer.
4. The method of claim 1, wherein the esophageal cancer is recurrent esophageal cancer, optionally, locally recurrent esophageal cancer, and / or metastatic esophageal cancer, optionally, distant metastatic esophageal cancer.
5. The method according to any one of claims 1 to 4, wherein the esophageal cancer exhibits resistance to at least one chemotherapy drug, and the chemotherapy drug is selected from the following group: taxane anti-tumor chemotherapy drugs, fluorouracil drugs or platinum drugs.
6. The method according to claim 5, wherein the taxane anti-tumor chemotherapy drug is selected from the group consisting of paclitaxel or docetaxel.
7. The method according to claim 5, wherein the fluorouracil drug is selected from the group consisting of 5-fluorouracil, S-1, or capecitabine.
8. The method according to claim 5, wherein the platinum drug is selected from the group consisting of cisplatin, carboplatin or oxaliplatin.
9. The method according to any one of claims 1-4, wherein the esophageal cancer exhibits resistance to immunotherapy.
10. The method according to any preceding claim, wherein the individual has received radiotherapy and / or chemotherapy.
11. The method according to any preceding claim, wherein the individual has received treatment for primary lesions and / or metastatic lesions.
12. A method according to any preceding claim, wherein the porphyrin dimer salt has a structure shown in formula (I), formula (II) or formula (III): in R is independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy and C 1-6 acyl, which is optionally substituted by one or more substituents selected from halogen and hydroxy, M is an alkali metal, an alkaline earth metal or NH4 + , p is the reciprocal of the valence number of M.
13. The method according to claim 12, wherein R is independently selected from C optionally substituted by one or more hydroxyl groups. 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Acyl, M is an alkali metal or NH4 + , and p is 1.
14. The method according to claim 13, wherein R is independently selected from -CH=CH2, -CH(OH)CH3 and -COCH3, and M is an alkali metal or NH4 + , and p is 1.
15. The method according to claim 14, wherein R is independently selected from -CH=CH2 and -CH(OH)CH3, and M is an alkali metal or NH4 + , and p is 1.
16. A process according to any one of claims 12 to 15, wherein M is an alkali metal.
17. The method of claim 16, wherein M is Na or K.
18. The method according to claim 12, wherein the porphyrin dimer salt bound by an ether bond is selected from Bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether, Bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether, 1-[6,7-dipropionic acid sodium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionic acid sodium-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether, Bis[1-[6,7-dipropanoic acid potassium-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether, Bis[1-[6,7-dipropanoic acid potassium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether, 1-[6,7-dipropionate potassium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionate potassium-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether, Bis[1-[6,7-dipropionate ammonium-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether, Bis[1-[6,7-dipropionate ammonium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether, and 1-[6,7-dipropionate ammonium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionate ammonium-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether.
19. The method according to any one of claims 12 to 18, wherein the porphyrin dimer salt is administered in the range of 0.01-5 mg / kg body weight.
20. The method according to any preceding claim, wherein the subject is subjected to photodynamic therapy using laser light 24-48 hours after administration of the porphyrin dimer salt.
21. The method according to claim 20, wherein the wavelength of the laser light is 631±3 nm, such as 630 nm, 631 nm or 632 nm.
22. The method according to claim 20 or 21, wherein the laser dose is 90-300 J / cm 2 .
23. The method of any preceding claim, wherein the immune checkpoint inhibitor is administered to the individual a period of time after the laser application.
24. The method of claim 23, wherein the immune checkpoint inhibitor is administered to the individual 20 to 50 hours (optionally 24 to 48 hours) after the laser administration.
25. The method according to claim 23 or 24, wherein the immune checkpoint inhibitor is selected from the group consisting of a PD-1 antagonist and a PD-L1 antagonist, wherein the PD-1 antagonist is optionally a PD-1 antibody, and the PD-L1 antagonist is optionally a PD-L1 antibody.
26. The method of claim 25, wherein the PD-1 antibody comprises Pembrolizumab, Nivolumab, Cemiplimab, Toripalimab, Sintilimab, Camrelizumab, Tislelizumab, Penpulimab, Sepalimab, Serplulimab and Putelimumab.
27. The method of claim 25, wherein the PD-L1 antibodies include Atezolizumab, Avelumab, Durvalumab, Envafolimab, and Sugemalimab.
28. The method of any preceding claim, wherein the porphyrin dimer salt is DVDMS-1, DVDMS-2, DVDMS-3 or DVDMS-M, and wherein the immune checkpoint inhibitor is pembrolizumab.
29. Use of a photosensitizer comprising a porphyrin dimer salt as defined in claims 12 to 18 in the preparation of a medicament for treating esophageal cancer in an individual, the treatment comprising the combination of the photosensitizer and an immune checkpoint inhibitor, optionally wherein the cancer or the individual is as defined in claims 1-11.
30. A photosensitizer suitable for treating cancer in an individual, wherein the photosensitizer comprises a porphyrin dimer salt as defined in claims 12 to 18, and the photosensitizer is administered in combination with an immune checkpoint inhibitor.
31. The photosensitizer according to claim 30, wherein the immune checkpoint inhibitor is as defined in claims 25 to 27.
32. The photosensitizer according to claim 30 or 31, wherein the porphyrin dimer salt is administered in the range of 0.01-5 mg / kg body weight.
33. The photosensitizer according to any one of claims 30 to 32, wherein the subject is subjected to photodynamic therapy using laser light 24 hours after administration of the porphyrin dimer salt.
34. The photosensitizer according to claims 30-33, wherein the wavelength of the laser is 631±3 nm, such as 630 nm, 631 nm or 632 nm.
35. The photosensitizer according to claim 33-34, wherein the dose of the laser is 90-300 J / cm 2 .
36. The photosensitizer of claims 33-35, wherein the immune checkpoint inhibitor is administered to the individual a period of time after the laser application.
37. A photosensitizer according to claims 33-36, wherein the immune checkpoint inhibitor is administered to the individual 20 to 50 hours (optionally 24 to 48 hours) after the laser application.
38. A photosensitizer according to claims 30-37, wherein the cancer or the individual is as defined in claims 1-11.
Citation Information
Patent Citations
Ether-linked porphyrin dimer salt and preparation method thereof
CN102030765B
Ether-linked porphyrin dimer salt and preparation method thereof
CN102030765A
Porphyrin dimer salt complex loaded with targeting polypeptide-modified ferritin nanoparticles and use and preparation method thereof
CN105396135A
PEGylated graphene oxide-porphyrin dimer salt complex and use thereof
CN105582541A
Nano preparation for tumor photodynamic therapy combined with immunotherapy
CN109381428A
Cited By
Mitochondrial targeting photosensitizer, preparation method and application thereof, and medicine box containing mitochondrial targeting photosensitizer
CN119528943A
Mitochondria-targeted photosensitizer, preparation method and use thereof, and kit containing the same
CN119528943B
